🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Recurrent Acute Lymphoblastic Leukemia

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention NCT06686108Phase 21 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax CAV Regimen for R/R Ph- B-ALL NCT05657652NA1 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: cladribine, cytarabine,venetoclax Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT07572136Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: TSLPR-CART, Cyclophosphamide, Fludarabine CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site📍 Prague Institute of Hematology and Blood Transfusion, Czech Republ… · Tests: Autologous CAR19 T lymphocytes VHAG in Treating R/R T-ALL/LBL NCT06742463Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: Venetoclax, homoharringtonine, Cytarabine (Ara-C), G-CSF Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia NCT03263572Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Blinatumomab, Cytarabine, Methotrexate, Ponatinib Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia NCT05366218Phase 1, Phase 211 sites📍 Freiburg im Breisgau📍 Tübingen📍 Ulm University Hospital Tuebingen · Tests: Tafasitamab Venetoclax Basket Trial for High Risk Hematologic Malignancies NCT05292664Phase 15 sites📍 San Francisco📍 Aurora📍 Atlanta Andrew E. Place, MD · Tests: Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia NCT07371403NA1 site📍 Amman King Hussein Cancer Center · Tests: MB-CART19.1 Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia NCT07133997Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab NCT06287229Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD, Mini-hyper-CVD Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors NCT03934372Phase 1, Phase 223 sites📍 Ghent📍 Paris📍 Paris Incyte Biosciences International Sàrl · Tests: Ponatinib HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant NCT03326921Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection A Study of CTD402 in T-ALL/LBL Patients NCT07070219Phase 1, Phase 29 sites📍 Palo Alto📍 Denver📍 Chicago Imviva Bio · Tests: CTD402 CAR T Cell Injection CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies NCT05442515Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma NCT07075328Phase 1, Phase 25 sites📍 Fukuoka📍 Sapporo📍 Kagoshima Otsuka Medical Devices Co., Ltd. Japan · Tests: Drug:5-ALA, Device:Photodynamic system Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia NCT07105579Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: BITE and DLI Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients NCT07039877Phase 21 site📍 Monterrey Hospital Universitario Dr. Jose E. Gonzalez · Tests: Venetoclax low dose with itraconazole A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT04546399Phase 2227 sites📍 Birmingham📍 Mobile📍 Anchorage National Cancer Institute (NCI) · Tests: 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bon… NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) NCT07502118Phase 2, Phase 34 sites📍 Ankara📍 Ankara📍 Ankara Health Institutes of Turkey · Tests: Talikabtagene Autoleucel Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling NCT05857969Phase 11 site📍 Miami Florida International University · Tests: Functional Precision Medicine CD7 CAR-T Cells in T-cell Lymphoma/Leukemia NCT05620680NA1 site📍 Shenzhen Shenzhen University General Hospital · Tests: CD7 CAR-T cells Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia NCT06845592NA1 site📍 Perugia University Of Perugia · Tests: total marrow/lymphoid irradiation Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia NCT03128034Phase 1, Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pretargeted Rad… Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies NCT05705570Phase 11 site📍 São Paulo Nelson Hamerschlak · Tests: Cyclophosphamide, Fludarabine, Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day… HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies NCT05658640Phase 1, Phase 236 sites📍 Vienna📍 Ghent📍 Copenhagen Princess Maxima Center for Pediatric Oncology · Tests: Trametinib, Dexamethasone, Cyclophosphamide, Cytarabine, Intrathecal chemotherapy Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) NCT01853631Phase 12 sites📍 Houston📍 Houston Baylor College of Medicine · Tests: Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy